Comparison of triple anti-platelet therapy and dual anti-platelet therapy in patients with acute myocardial infarction who had no-reflow phenomenon during percutaneous coronary intervention

Circulation Journal

Volumn 77, Issue 12, 2013, Pages 2973-2981

  Lee, Ki Hong ^a   Ahn, Youngkeun ^a   Kim, Sung Soo ^a   Rhew, Shi Hyun ^a   Jeong, Young Wook ^a   Jang, Soo Young ^a   Cho, Jae Yeong ^a   Jeong, Hae Chang ^a   Park, Keun Ho ^a   Yoon, Nam Sik ^a   Sim, Doo Sun ^a   Yoon, Hyun Ju ^a   Kim, Kye Hun ^a   Hong, Young Joon ^a   Park, Hyung Wook ^a   Kim, Ju Han ^a   Cho, Jeong Gwan ^a   Park, Jong Chun ^a   Jeong, Myung Ho ^a   Cho, Myeong Chan ^b   Kim, Chong Jin ^c   Kim, Young Jo ^d   more..

^a Chonnam National University Medical School   (South Korea)

^b Chungbuk National University Hospital   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

^d Young Nam University Hospital   (South Korea)

Author keywords

Cilostazol; Myocardial infarction; No reflow phenomenon

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CORONARY ARTERY BYPASS GRAFT; DEATH; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; NO REFLOW PHENOMENON; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; SURVIVAL RATE;

EID: 84888245190     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0594     Document Type: Article

References (27)

1. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-refow in humans. J Am Coll Cardiol 2009; 54: 281-292.
2. Rezkalla SH, Kloner RA. Coronary no-refow phenomenon: From the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2008; 72: 950-957.
3. Henriques JP, Zijlstra F, van't Hof AW, de Boer MJ, Dambrink JH, Gosselink M, et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 2003; 107: 2115-2119.
4. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI myocardial perfusion grades, fow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105: 1909-1913.
5. McLaughlin MG, Stone GW, Aymong E, Gardner G, Mehran R, Lansky AJ, et al. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. J Am Coll Cardiol 2004; 44: 1215-1223.
6. Bolognese L, Carrabba N, Parodi G, Santoro GM, Buonamici P, Cerisano G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004; 109: 1121-1126.
7. Galiuto L, Garramone B, Scara A, Rebuzzi AG, Crea F, La Torre G, et al. The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: Results of the multicenter AMICI study. J Am Coll Cardiol 2008; 51: 552-559.
8. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, et al. Prognostic signifcance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97: 765-772.
9. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 1988; 36: 313-320.
10. Nakamura N, Hamazaki T, Johkaji H, Minami S, Yamazaki K, Satoh A, et al. Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. Clin Exp Med 2003; 2: 180-184.
11. Golino P, Maroko PR, Carew TE. The effect of acute hypercholes-terolemia on myocardial infarct size and the no-refow phenomenon during coronary occlusion-reperfusion. Circulation 1987; 75: 292-298.
12. Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, et al. Clinical signifcance of no-refow phenomenon observed on angiog-raphy after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995; 130: 239-243.
13. Lee MG, Jeong MH, Ahn Y, Cho JG, Park JC, Kang JC, et al. Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome. Circ J 2011; 75: 2120-2127.
14. Choi YH, Suh SH, Choi JS, Kim CS, Sim DS, Bae EH, et al. Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction. Circ J 2012; 76: 2405-2411.
15. Kataoka Y, Yagi N, Kokubu N, Kasahara Y, Abe M, Otsuka Y. Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction. Circ J 2011; 75: 1968-1974.
16. Park KW, Kim HS. Options to overcome clopidogrel response variability. Circ J 2012; 76: 287-292.
17. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforsc-hung 1985; 35: 1144-1149.
18. Collet JP, Montalescot G. The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes. Diab Vasc Dis Res 2005; 2: 136-143.
19. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. Drug-eluting stenting followed by cilostazol treatment reduces late reste-nosis in patients with diabetes mellitus: The DECLARE-DIABETES Trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol 2008; 51: 1181-1187.
20. Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study. Am Heart J 2009; 157: 733-739.
21. Lee SW, Chun KJ, Park SW, Kim HS, Kim YH, Yun SC, et al. Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Am J Cardiol 2010; 105: 168-173.
22. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 2007; 100: 1103-1108.
23. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, et al. Triple versus dual antiplatelet therapy after coronary stenting: Impact on stent thrombosis. J Am Coll Cardiol 2005; 46: 1833-1837.
24. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992; 20: 900-906.
25. Morishita R. A scientifc rationale for the CREST trial results: Evidence for the mechanism of action of cilostazol in restenosis. Athero-scler Suppl 2005; 6: 41-46.
26. Kim JS, Lee KS, Kim YI, Tamai Y, Nakahata R, Takami H. A randomized crossover comparative study of aspirin, cilostazol and clop-idogrel in normal controls: Analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004; 11: 600-602.
27. Comerota AJ. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. Atheroscler Suppl 2005; 6: 13-19.